Billy Costa talks with Dr. Salvia Jain to learn more about the treatments and therapies available for patients with T-cell lymphoma.
Salvia Jain, MD
Salvia Jain, MD
Assistant Professor of Medicine, Harvard Medical School
Departments, Centers, & Programs:
Mass General Cancer Center: Hematology Oncology
55 Fruit St.
Boston, MA 02114
- MBBS, Mahatma Gandhi Missions Medical College
- Residency, Tufts Medical Center
- Fellowship, New York University Medical Center
- Fellowship, Stanford Hospital and Clinics
Accepted Insurance Plans
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Dr Jain's preclinical research has been translated into several multicenter clinical trials including combinations of HDAC inhibitors with anti-folates, Mucin-1 inhibitor with DNA methyltransferase inhibitors and most recently CD47-SIRPa antagonists with anti-CCR4 antibodies. She leads numerous investigator-initiated clinical trials of novel agents and their combinations including large national and global cohort-based studies for patients with T-cell lymphomas. On the laboratory side she utilizes a spectrum of single cell technologies and diverse spectrum of patient-derived and transgenic mouse models to define mechanisms underlying response resistance to immunotherapeutics in T-cell lymphomas. The laboratory works across a wide range of areas such as delineating molecular mechanisms of response and resistance to CD47 blocking therapies, investigating novel checkpoint strategies, and elucidating regulators of phagocytosis in T-cell lymphomas.
For list of publications use: https://pubmed.ncbi.nlm.nih.gov/?term=Salvia+Jain